✦ LIBER ✦

Development of a long acting human growth hormone analog suitable for once a week dosing

✍ Scribed by Palanki, Moorthy S.S.; Bhat, Abhijit; Bolanos, Ben; Brunel, Florence; Del Rosario, Joselyn; Dettling, Danielle; Horn, Mark; Lappe, Rodney; Preston, Ryan; Sievers, Annette; Stankovic, Nebojsa; Woodnut, Gary; Chen, Gang

Book ID: 121998596
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 593 KB
Volume: 23
Category: Article
ISSN: 0960-894X
DOI: 10.1016/j.bmcl.2012.11.104

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P20 Pharmacokinetic-pharmacodynamic mode

P20 Pharmacokinetic-pharmacodynamic model for a pegylated, long-acting human growth hormone developed for once-weekly administration

✍ M.H. Rasmussen; T. Klitgaard; J. Madsen 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 44 KB

Discovery of a Rapidly Metabolized, Long

Discovery of a Rapidly Metabolized, Long-Acting β 2 Adrenergic Receptor Agonist with a Short Onset Time Incorporating a Sulfone Group Suitable for Once-Daily Dosing

✍ Procopiou, Panayiotis A.; Barrett, Victoria J.; Biggadike, Keith; Butchers, Pete 📂 Article 📅 2013 🏛 American Chemical Society 🌐 English ⚖ 525 KB

Multiple doses of pegylated long-acting

Multiple doses of pegylated long-acting growth hormone are well tolerated in healthy male volunteers and possess a potential once-weekly treatment profile

✍ Michael Højby Rasmussen; Lene Jensen; Thomas W. Anderson; Thomas Klitgaard; Jesp 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 339 KB

Comparison of a single half-dose, long-a

Comparison of a single half-dose, long-acting form of gonadotropin-releasing hormone analog (GnRH-a) and a short-acting form of GnRH-a for pituitary suppression in a controlled ovarian hyperstimulation program

✍ Yao-Yuan Hsieh; Horng-Der Tsai; Chi-Chen Chang; Chi-Chia Chang; Hui-Yu Lo 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 59 KB

PO2-12: Development and characterization

PO2-12: Development and characterization of manufacturing process of MOD-4023, a long acting human growth hormon to support clinical and commercial supply

✍ Hershkovitz, O.; Moschovich, L.; Yana Felikman, Y.; Guy, R.; Fima, E. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 446 KB

P-48 A PK/PD model for characterisation

P-48 A PK/PD model for characterisation of NNC 126-0083, a long-acting growth hormone derivative with respect to efficacy, time of duration and dose selection

✍ P. Thygesen; H. Agersø 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 51 KB